

Research: Grants and Contracts from Industry

- 1985-1986** A Bacteriologically Controlled, Comparative Study of the Safety, Tolerance, and Efficacy of Timentin with Gentamicin/Clindamycin in the Treatment of Hospitalized Patients with Intra-Abdominal Infections, Beecham Laboratories, Bristol, TN
- 1985-1986** Incidence of Pulmonary Complications in Severely Injured Trauma Patients Managed on a Conventional Hospital Bed or the Kinetic Treatment Table, Kinetic Concepts, Inc., San Antonio, TX.
- 1988** Lung Bacterial and Nonbacterial Particulate Clearance After Blunt Thoracic Trauma in Anesthetized Yucatan Minipigs: Effect of Continuous Postural Oscillation using a Kinetic Treatment Table, Kinetic Concepts, Inc., San Antonio, TX.
- 1988-1989** Double Blind, Multicenter, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of HA-1A Human Monoclonal Antibody in Patients with Severe Gram-Negative Sepsis/Gram-Negative Septic Shock, Centocor, Inc., Malvern, PA.
- 1989** Gastric Intramural pH Values in Healthy Human Subjects, Tonometrics, Inc., Bethesda, MD.
- 1989-1990** A Randomized, Open-Label, Comparative, Multicenter, Safety, Tolerance and Efficacy Study of Parenteral Piperacillin/Tazobactam (CL 298, 741) Versus Clindamycin Plus Gentamicin in the Treatment of Hospitalized Patients with Intra-Abdominal Infections, Lederle Laboratories, Pearl River, New York.
- 1990** Amelioration of Intramucosal Intestinal Acidosis in Resuscitated Endotoxic Pigs: Therapeutic Efficacy of LY203647, a Leukotriene D₄E₄ Antagonist, Eli Lilly & Company, Indianapolis.
- 1990-1991** Prospective, Controlled, Third-Party Blind, Randomized Study Comparing the Efficacy and Safety of Intravenous Ciprofloxacin with Intravenous Imipenem for the Treatment of Patients with Nosocomial Pneumonia, Miles, Inc., West Haven, CT.
- 1990-1992** Prospective, Controlled, Third-Party Blind, Randomized, Multi-Center Comparison of the Safety and Efficacy of Ciprofloxacin plus Metronidazole (IV Only and IV/PO with that of Imipenem-Cilastatin for the Treatment of Patients with Intra-Abdominal Infections, Miles, Inc., West Haven, CT.
- 1990-1991** Phase I/II Clinical Trial to Evaluate the pharmacokinetics, Safety, and Immunogenicity of Multiple Doses of HA-1A Human Monoclonal Antibody in High-Risk Surgical Patients, Centocor, Inc., Malvern, PA.
- 1991** Effect of G-CSF-Induced Neutrophilia on the Response to Endotoxin in Anesthetized Pigs, Amgen, Inc., Thousand Oaks, CA.
- 1991-1992** Effect LY255283, a Leukotriene B₄ Receptor Antagonist, on the Response to Endotoxin in Anesthetized Pigs, Eli Lilly & Company, Indianapolis, IN.
- 1992** A Study to Evaluate the Safety and Efficacy of Human Recombinant Interleukin-1 Receptor Antagonist (IL-1RA) in the Treatment of Sepsis Syndrome, Synergen, Inc., Boulder, CO.
- 1994** Effect of BPI₂₃ in a porcine model E.coli bacteremia, Xoma, Inc., Berkeley, CA
- 1994** Evaluation of CAP 18 in septic rats and pigs, Amgen, Inc., Thousand Oaks, CA
- 1994** Effect of murine monoclonal antibody T88 on mortality and cytokine release in septic rats, Chiron, Inc., Berkeley, CA
- 1994** Effect of three serine protease inhibitors on endotoxin-Induced acute lung injury in swine, Eli Lilly, Inc., Indianapolis, IN
- 1994** Polymyxin-B/Dextran conjugates in sepsis, Sandoz Research Institute, East Hanover, NJ
- 1994** Effects of dantrolene sodium in septic rats and pigs, Proctor & Gamble, Inc., Norwich, NY
- 1995-1998** Evaluation of recombinant human tissue factor pathway for adjuvant treatment of sepsis in rabbits, Chiron, Inc., Emoryville, CA

- 1996** Evaluation of recombinant human hemoglobin (rHb1.1) in a rat model of hemorrhage and sepsis, Somatogen, Boulder, CA
- 1997** Mechanism of action of lisofylline as cytoprotective agent in the gut, Cell Therapeutics, Inc., Seattle, WA
- 1997** Nitric oxide scavengers in inflammatory bowel disease, AnorMED, Inc., Langley, BC
- 1997-1998** Tissue factor pathway inhibitor for the treatment of septic shock. Chiron, Inc., El Cerrito, CA
- 2002-2003** Evaluation of recombinant human activated protein C and related constructs in murine models of endotoxemia and sepsis. Maxygen, Inc., Copenhagen, Denmark

Grants and Contracts from Foundations:

- 1985-1986 Abnormal regulation of peripheral vasomotor tone in sepsis (Grant-in-Aid #13-540-856), American Heart Association, Massachusetts Affiliate, Needham, MA.